An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

295

Participants

Timeline

Start Date

October 14, 2015

Primary Completion Date

December 16, 2019

Study Completion Date

December 16, 2019

Conditions
Solid Tumors
Interventions
DRUG

BMS-986156

DRUG

Nivolumab

Trial Locations (27)

2145

Local Institution, Westmead

2170

Liverpool Cancer Therapy Center, Liverpool

4102

Princess Alexandra Hospital, Brisbane

6009

Linear Clinical Research Ltd, Nedlands

8091

Local Institution, Zurich

9000

Local Institution - 0012, Ghent

9007

Cantonal Hospital St. Gallen, Sankt Gallen

19107

Thomas Jefferson University Hospital, Philadelphia

20133

Local Institution - 0014, Milan

20141

Local Institution - 0015, Milan

28040

Local Institution, Madrid

28041

Local Institution, Madrid

30322

Emory University, Atlanta

31059

Institut Claudius Regaud, Toulouse

38138

The West Clinic, P.C., Germantown

43210

The Ohio State University, Columbus

53127

Local Institution, Bonn

75248

Local Institution, Paris

79106

Local Institution, Freiburg im Breisgau

94800

Institut Gustave Roussy, Vlllejuif

97080

Local Institution, Würzburg

97213

Providence Portland Medical Center, Portland

35294-3300

University Of Alabama At Birmingham, Birmingham

92093-0698

UCSD Moores Cancer Center, La Jolla

T6G 1Z2

Local Institution, Edmonton

M5G 1Z5

Local Institution, Toronto

1066CX

Local Institution, Amsterdam

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY